Lv5
1322 积分 2024-01-16 加入
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
1天前
待确认
Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China
1个月前
已关闭
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?
1个月前
已完结
Advances in systemic therapies for triple negative breast cancer
1个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
1个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
Triple-Negative Breast Cancer
1个月前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
1个月前
已关闭
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2个月前
已完结
Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
